2 weeks Ago By Defense World Staff
Bokf Na boosted its position in shares of SPDR S&P Biotech ETF ( NYSEARCA:XBI – Free Report ) by 65.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,390 shares of the exchange traded fund’s stock after purchasing an additional 550 shares during the period.
Bokf Na’s holdings in SPDR S&P Biotech ETF were worth $129,000 at the end of the most recent reporting period. Other institutional investors have also recently bought and sold shares of the company. ICA Group Wealth Management LLC acquired a new stake in SPDR S&P Biotech ETF during the fourth quarter valued at $27,000.
Scarborough Advisors LLC bought a new stake in SPDR S&P Biotech ETF in the fourth quarter worth $32,000. BOCHK Asset Management Ltd bought a new stake in SPDR S&P Biotech ETF in the fourth quarter worth $36,000. ORG Partners LLC acquired a new position in SPDR S&P Biotech ETF during the second quarter worth $40,000.
Finally, Vima LLC acquired a new stake in shares of SPDR S&P Biotech ETF in the fourth quarter worth about $45,000. SPDR S&P Biotech ETF Stock Performance XBI opened at $100.93 on Wednesday.
The company has a market cap of $7.69 billion, a PE ratio of 11.47 and a beta of 1.
11. The stock has a 50-day moving average of $98.65 and a 200-day moving average of $93.
87. SPDR S&P Biotech ETF has a 52-week low of $63.80 and a 52-week high of $103.
52. SPDR S&P Biotech ETF Profile SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index.
The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. Featured Articles Five stocks we like better than SPDR S&P Biotech ETF Using the MarketBeat Stock Split Calculator Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? Conference Calls and Individual Investors Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours? Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.
com's FREE daily email newsletter ..
